These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
664 related articles for article (PubMed ID: 31879210)
1. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210 [TBL] [Abstract][Full Text] [Related]
2. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187 [TBL] [Abstract][Full Text] [Related]
3. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
4. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605 [TBL] [Abstract][Full Text] [Related]
6. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. Ishida T; Ciulli A SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537 [TBL] [Abstract][Full Text] [Related]
7. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders. Setia N; Almuqdadi HTA; Abid M Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162 [TBL] [Abstract][Full Text] [Related]
8. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Guo WH; Qi X; Yu X; Liu Y; Chung CI; Bai F; Lin X; Lu D; Wang L; Chen J; Su LH; Nomie KJ; Li F; Wang MC; Shu X; Onuchic JN; Woyach JA; Wang ML; Wang J Nat Commun; 2020 Aug; 11(1):4268. PubMed ID: 32848159 [TBL] [Abstract][Full Text] [Related]
9. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579 [TBL] [Abstract][Full Text] [Related]
10. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. Tinworth CP; Lithgow H; Dittus L; Bassi ZI; Hughes SE; Muelbaier M; Dai H; Smith IED; Kerr WJ; Burley GA; Bantscheff M; Harling JD ACS Chem Biol; 2019 Mar; 14(3):342-347. PubMed ID: 30807093 [TBL] [Abstract][Full Text] [Related]
11. Site-Specific Labeling of Endogenous Proteins Using CoLDR Chemistry. Reddi RN; Rogel A; Resnick E; Gabizon R; Prasad PK; Gurwicz N; Barr H; Shulman Z; London N J Am Chem Soc; 2021 Dec; 143(48):20095-20108. PubMed ID: 34817989 [TBL] [Abstract][Full Text] [Related]
12. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151 [TBL] [Abstract][Full Text] [Related]
13. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel BTK PROTACs for B-Cell lymphomas. Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879 [TBL] [Abstract][Full Text] [Related]
15. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins. Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822 [TBL] [Abstract][Full Text] [Related]